Frankfurt - Delayed Quote EUR

Stoke Therapeutics, Inc. (0GT.F)

5.70

-0.10

(-1.72%)

As of 8:19:55 AM GMT+2. Market Open.

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

BEDFORD, Mass., April 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesda

Business Wire 9 days ago

STOK
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its latest annual results and things are looking bullish...

Simply Wall St. 20 days ago

STOK
Stoke Therapeutics Stock Slips as CEO Steps Down

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Investopedia 24 days ago

STOK
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 24 days ago

STOK
Stoke CEO exits; Medicare drug price talks advance

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.

BioPharma Dive 24 days ago

STOK

INCY

AZN
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

BEDFORD, Mass., March 18, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates.

Business Wire 24 days ago

STOK
Stoke Therapeutics Announces CEO Transition

BEDFORD, Mass., March 18, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome.

Business Wire 24 days ago

STOK
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 25 days ago

STOK
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 25 days ago

ARGX

STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in March

BEDFORD, Mass., February 26, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:

Business Wire last month

STOK
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.

Pharmaceutical Technology last month

STOK

BIIB
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following the alignm

Benzinga last month

STOK

BIIB
$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

CAMBRIDGE, Mass. & BEDFORD, Mass., February 18, 2025--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying

Business Wire last month

STOK

BIIB
Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

BioPharma Dive last month

BIIB

STOK
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?

Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 2 months ago

STOK

ANIK
The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%

While Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders are probably generally happy, the stock hasn't had...

Simply Wall St. 2 months ago

STOK
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.

Zacks 2 months ago

STOK
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., January 08, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).

Business Wire 2 months ago

STOK
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.

BioPharma Dive 3 months ago

SANA

STOK
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass., January 07, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced alignment with global regulatory agencies on the design of the Company’s Phase 3 EMPEROR study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.

Business Wire 3 months ago

STOK

Performance Overview

Return	0GT.F	S&P 500 (^GSPC)
YTD	-45.71%	-9.12%
1-Year	-51.28%	+2.81%
3-Year	-72.60%	+21.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Stoke Therapeutics, Inc. (0GT.F)

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Stoke Therapeutics Stock Slips as CEO Steps Down

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke CEO exits; Medicare drug price talks advance

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Stoke Therapeutics Announces CEO Transition

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?

The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Performance Overview